Please find enclosed herewith the Intimation regarding the Re-appointment of Mr. Yogesh K. Varia as an Independent Director of the Company, for a second term of 5 consecutive years w.e.f. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parnax Lab Ltd's Board approved the re-appointment of Mr. Yogesh K. Varia as Non-Executive Independent Director for a second term of 5 years (May 28, 2026 to May 27, 2031), subject to shareholder approval. The Board also approved audited standalone and consolidated financial results for the year ended March 31, 2026. Standalone revenue declined to Rs. 662.51 lakhs from Rs. 701.90 lakhs, with net profit of Rs. 88.75 lakhs versus Rs. 139.46 lakhs in prior year. Consolidated revenue grew significantly to Rs. 24,854.43 lakhs from Rs. 18,773.78 lakhs, with net profit of Rs. 1,177.68 lakhs (attributable to owners). The company has one subsidiary, Naxpar Pharma Private Limited. Statutory auditors C.N. Patel & Co. issued an unmodified opinion on both standalone and consolidated results.
The re-appointment of the independent director maintains board continuity and governance stability. The standalone business showed declining performance, but the consolidated group results reflect strong growth driven by the subsidiary. The unmodified auditor opinion is positive for investors.